Posted on

The cure for constant hunger

TRYP THERAPEUTICS SUBMITS IND APPLICATION FOR PHASE 2A CLINICAL TRIAL IN EATING DISORDERS

Can shrooms treat this rare genetic disorder?

Tryp Therapeutics (TRYP) is preparing for a Phase 2a study on overeating disorders including a rare condition called Prader-Willi Syndrome, a genetic disorder that causes intellectual disability, shortness in height, and constant hunger than often leads to obesity and diabetes.

The clinical trial is expected to begin in Q4 of this year and will investigate various other eating disorders such as binge eating and hypothalamic obesity. Ten patients will be given two doses of psilocybin, which in theory will increase neuroplasticity to create healthier neural patterns related to eating habits.

The San Diego company just filed a Investigational New Drug (IND) application with the FDA, for TRP-8802, the psilocybin formulation that will be used in the study.

PDF of article

Posted on

Say goodbye to extreme anxiety

Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Mydecine Innovations Group (MYCO) filed a patent for a new anxiety and PTSD drug that provides more immediate relief than pure psilocybin.

The compound, MYCO-003, combines a serotonin agonist with a serotonin releasing agent – two drug classes that increase one’s sense of well-being, safety, and happiness. The formulation has shown positive preclinical data and has potential to relieve extreme anxiety before needing to provide extensive supportive care, according to the Chief Science Officer.

The patent was filed with both the United States Patent and Trademark Office (USPTO) and the World Intellectual Property Organization (WIPO).

PDF of article

Posted on

Reducing fish seizures

Lead program, BMB-101, advances to IND-enabling toxicology studies with the aim of commencing human trials in 1H 2022

This Vancouver company is making advancements across its drug pipeline.

Bright Minds Biosciences (DRUG) selected Dravet Syndrome, a disorder that causes epilepsy from a young age, as the lead indication for its 5-HT2C formulation, BMB-101. In preclinical studies on zebrafish, BMB-101 was effective in reducing seizure duration and frequency and is now on track to be tested in human trials early next year.

In rat models, BMB-101 showed efficacy in treating opioid use disorder and binge eating disorder with rats demonstrating a 50% reduction in binge eating episodes.

The company also has a 5-HT2A + 5-HT2C mixed compound that is in preclinical development for cluster headaches, chemotherapy-induced peripheral neuropathy, and other pain disorders. Researchers are currently screening 5-HT2A compounds for depression as well.

PDF of article

Posted on

Tapping into traditional healing

Goodness Growth Holdings™ Subsidiary Resurgent Biosciences Launches First IRB-Approved Research Study on Entheogens & Psychedelic Experiences

Resurgent Biosciences, a subsidiary of Goodness Growth Holdings (GDNS), is tapping into the spiritual and cultural side of psychedelics to develop a better approach to psychedelic therapy.

The company is launching a study on the naturalistic use of entheogens through a partnership with Flor da Jurema, a temple community in Brazil where visitors can take part in spiritual experiences with traditional plant medicines.

The study, which was just approved by an independent Institutional Review Board, will survey 100 adults who have participated in entheogen therapy centers or psychedelic retreats in the last five years.

The goal is to get a sense of their intentions, motivations, experiences, demographics, and willingness to participate in entheogen research in the future and use the findings to create more positive, long-lasting results from psychedelic-assisted therapies.

PDF of article

Posted on

Suicide is never the answer…

Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer

But psychedelics might be!

Conventional SSRI antidepressants are often ineffective in reducing suicidality and have even been known to increase suicidal thoughts. Psychedelics could be a revolutionary solution.

An NYU study found that psilocybin-assisted psychotherapy significantly reduced suicidal ideation in advanced cancer patients. Patients saw improvements in existential distress as early as 8 hours after the first dose, and the positive effects lasted over 6 months after the second dose.

Posted on

Can this combination treat depression?

Allied Corp. Advances Psilocybin Product Psilonex™ RX and Initiates Manufacturing Process

Allied Corp. (ALID) has a new approach for treating depression, anxiety and PTSD.

The Kelowna-based company developed a proprietary formulation called Psilonex RX that combines psilocybin extract with functional mushroom extracts and a blend of vitamins.

Allied Corp. aims to treat patients by prescribing a dose of Psilonex RX followed by a daily dose of its CBD product, Psilonex Daily.

The company just began manufacturing Psilonex RX under an agreement with HAVN Life Sciences (HAVN).

Posted on

An accidental finding

Nova Mentis Expands Psilocybin Research Program Targets Obesity and Diabetes

Nova Mentis (NOVA) was studying the effect of psilocybin on rats with autism symptoms when they discovered an unexpected finding…

Not only did the psilocybin improve anxiety and cognitive function in the rats, but it also seemed to impact the proteins that regulate inflammation, indicating that the formulation may be able to treat obesity and diabetes related to obesity (“diabesity”).

Another highly promising indicator is that psilocybin activates the 5-HT2C serotonin receptors, which play a role in body weight and food intake. In fact, one of the current FDA-approved obesity treatments called lorcaserin is also a serotonin receptor agonist, but it can have lots of unwanted side effects that psilocybin would likely avoid!

Posted on

4x more effective than psilocybin?

Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose

A recent study revealed that psilocybin can increase neuronal connections by 10%, but a different psychedelic may be even more effective.

A Vancouver company called Algernon Pharmaceuticals Inc. (AGN) discovered that its propriety compound based on DMT increased the growth of cortical neurons by 40% –  even at sub-hallucinogenic doses!

In the study, the cortical neurons of rats were treated with varying concentrations of DMT for just one hour and were examined 3 days later.

From now til the end of October, the company will experiment with increasing this duration to up to 72 hours.

Posted on

Studying the most depressed patients

Braxia Scientific to Commence Landmark Clinical Trial to Conduct Canada’s First Multiple-Dose Psilocybin Clinical Trial for Treatment Resistant Depression

“This will be the broadest study of its kind.”

This morning, Braxia Scientific (BRAX) announced that it’s launching Canada’s first multiple-dose psilocybin trial for treatment resistant depression (TRD).

Most TRD studies recruit patients who have tried a maximum of five other treatment options, but this study will have no upper limit on the number of failed treatments. Braxia researchers will even include patients who’ve gone through dozens of medical trials with no success, including ketamine and electroconvulsive therapy patients.

The randomized clinical trial will also include some patients with bipolar depression or comormid disorders, which are typically excluded from psychedelic studies.

“By including everyone with more than two failed medical trials, we are increasing the degree to which the results can be applied to a larger population, making our findings much stronger”, said the trial’s principal investigator.

Posted on

Revolutionizing all of healthcare?

This West Philly Doctor Says Psychedelic-Assisted Therapy Could Change Your Life

Psychedelic therapy clinics continue to pop up across North America.

Last week, a nonprofit organization called SoundMind Center officially opened in West Philadelphia, which will be dedicated to psychedelic research, treatment, and therapist training.

On Tuesday, another clinic called Innerbloom Healing Arts opened in Charleston, South Carolina. Both clinics currently offer ketamine-assisted therapy with plans to offer MDMA and psilocybin therapy as soon as possible.

“Psychedelics are not only going to revolutionize mental health. They have the ability to revolutionize all of healthcare. Changing the way we think about the relationship between mind and body. And health and disease”, said Dr. Hannah McLane, SoundMind’s founder.